Anchyra Partners
UTHR icon

Anchyra Partners’s United Therapeutics UTHR Stock Holding History

Anchyra Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.06M Sell
1,949
-7
-0.4% -$3.62K 0.22% 84
2026
Q2 		$1.06M Buy
1,956
+4
+0.2% +$2.25K 0.25% 79
2026
Q1 		$1.16M Buy
1,952
+5
+0.3% +$2.49K 0.35% 56
2025
Q4 		$949K Buy
+1,947
New +$907K 0.29% 69

Other funds holding UTHR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Anchyra Partners's UTHR Position: Q3 2026 in Review

Anchyra Partners reduced its United Therapeutics (UTHR) stake by 0.36% in Q3 2026, selling an estimated $3.62K and leaving 1,949 shares worth $1.06M. The position accounts for 0.22% of the portfolio, ranked #84.

Anchyra Partners first reported a position in UTHR in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.16M in Q1 2026. 673 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Anchyra Partners held 1,949 shares of United Therapeutics worth $1.06M as of Q3 2026.
  • Anchyra Partners sold 7 United Therapeutics shares in Q3 2026, an estimated $3.62K.
  • United Therapeutics made up 0.22% of Anchyra Partners's portfolio in Q3 2026, its #84 holding.
  • Anchyra Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Anchyra Partners's United Therapeutics position peaked at $1.16M in Q1 2026.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Anchyra Partners's 13F filing for Q3 2026, filed 13 Oct 2026.